Swiss startup Vaderis raises $152 million to fund Phase 3 trial of rare bleeding disorder therapy
read at Endpoints ↗DealPositive
Vaderis Therapeutics, a 13‑person Swiss biotech, announced a $152 million Series B financing round aimed at advancing its experimental therapy into a Phase 3 study.
The company is testing a treatment originally designed for oncology indications in patients with a rare bleeding disorder, hoping the approach will translate to clinical benefit.
The new capital will support trial execution, regulatory interactions and further development activities as the firm seeks to bring the therapy to market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment”
read at Endpoints ↗89 words · retrieved Aug 11
comments(0)
5-min edit window · permanent after that